Background Catheter-based renal denervation has significantly reduced blood pressure in
previous studies. Following a positive pilot trial, the SPYRAL HTN-OFF MED (SPYRAL Pivotal…

Since the publication of the 2018 European Society of Cardiology/European Society of
Hypertension (ESC/ESH) Guidelines for the Management of Arterial Hypertension, several high-…

Arterial hypertension is the most prevalent modifiable risk factor associated with cardiovascular
morbidity and mortality. Although antihypertensive drugs are widely available, in many …

Arterial hypertension is a leading cause of death globally. Due to ageing, the rising incidence
of obesity, and socioeconomic and environmental changes, its incidence increases …

Background The renin-angiotensin-aldosterone system plays a key role in blood pressure (BP)
regulation and is the target of several antihypertensive medications. Renal denervation (…

Pulmonary embolism (PE) is the leading cause of in-hospital death and the third most frequent
cause of cardiovascular death. The clinical presentation of PE is variable, and choosing …

Background Renal denervation (RDN) has been shown to lower blood pressure (BP), but its
effects on cardiovascular events have only been preliminarily evaluated. Time in …

Background The spread of the novel coronavirus SARS-CoV-2 and the guidance from
authorities for social distancing and media reporting lead to significant uncertainty in Germany. …

Background Single‐electrode ablation of the main renal artery for renal sympathetic
denervation showed mixed blood pressure ( BP )‐lowering effects. Further improvement of the …

Aims Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization
in patients with HF and preserved ejection fraction. This study aims to evaluate if systolic …